ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 181

Thiopurine S-Methyltransferase Levels in Patients with Behçet’s Disease

Hakan Emmungil1, Melike Kalfa2, Raika Durusoy3, Figen Yargucu Zihni2, Gokhan Keser4 and Kenan Aksu2, 1Rheumatology, Mersin State Hospital, Mersin, Turkey, 2Dept. of Internal Medicine, Division of Rheumatology, Ege University, Dept. of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey, 3Department of Public Health, Ege University, Department of Public Health, Ege University, Izmir, Turkey, 4Dept. of Internal Medicine, Division of Rheumatology, Ege University School of Medicine, Izmir, Turkey

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: adverse events and azathioprine, Behcet's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Azathioprine (AZA) is an immunosuppressive agent which is widely used not only for the treatment of Behcet’s disease (BD), but also for the treatment of many systemic inflammatory diseases including systemic lupus erythematosus (SLE) and various systemic vasculitis. Thiopurine S-methyltransferase (TPMT) is a genetically moderated key enzyme involved in the metabolism of AZA. Low TPMT levels may cause a tendency for AZA-related adverse effects. In the present study, TPMT levels in patients with BD were compared with healthy controls, as well as with patients with SLE or with systemic vasculitis, as disease control groups. We investigated the relationship between TPMT levels and AZA-related adverse effects, and also whether TPMT levels were affected by AZA treatment.

Methods:

In the present cross-sectional study, 101 patients with BD (M/F: 61/40; mean age 42.15±10.33 years), 74 patients with SLE (M/F: 11/63; mean age: 39.86±11.69 years), 44 patients with systemic vasculitis (M/F: 21/23; mean age 47.09±13.36 years) and 101 healthy controls, age and sex matched with BD were included. Detailed past medical data were available for all patients. The TPMT activity in red blood cells was measured using ELISA. AZA was stopped three days before measurements in patients already receiving this drug. Data were presented as mean ± SD. Mean TPMT levels (mIU/ml) were compared with Student’s t, Mann Whitney U and Kruskal Wallis tests, and Receiver Operating Characteristic (ROC) analysis was used to determine whether TPMT could be used to predict toxicity.

Results:

Mean TPMT levels in BD (22.80±13.81) were comparable with healthy controls (22.71±13.49), but significantly lower than in patients with SLE (29.37±11.39) (p<0.001). There were 130 patients, 77 with BD, 35 with SLE, and 18 with systemic vasculitis who had used or have been currently using AZA treatment. TPMT levels were not significantly different between patients with and without AZA treatment. AZA-related adverse effects involving gastrointestinal tract, liver and bone marrow were identified in 8 out of 130 patients (5 with BD and 3 with SLE). Although the mean TPMT levels were significantly lower in patients suffering from AZA-related adverse effects (14.08±9.49) than in patients without adverse effects (25.62±12.68) (p=0.013), a cut-off value for predicting AZA-related adverse effects could not be determined with ROC analysis (Area under the curve: 0.249).

Conclusion: This was the first study evaluating TPMT activity in Turkish adult population. Despite more frequent AZA-related adverse effects in the presence of low TPMT levels, absence of a certain cut-off value for TPMT levels implicate that variation in the level of this enzyme may not be the only factor determining AZA-related adverse events. Clinical relevance of TPMT testing should further be determined with larger prospective studies.


Disclosure:

H. Emmungil,
None;

M. Kalfa,
None;

R. Durusoy,
None;

F. Yargucu Zihni,
None;

G. Keser,
None;

K. Aksu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/thiopurine-s-methyltransferase-levels-in-patients-with-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology